Nebenwirkungen · Imbruvica
IMBRUVICA 140 mg hard capsules · Abschnitt 4.8 · PDF-Seite 11–12
HOS-131624 · Präparat HOS-097103
11 Respiratory, Very Cough* 24 <1 thoracic and common mediastinal disorders Gastrointestinal Very Diarrhoea 47 4 disorders common Vomiting 15 1 Stomatitis* 17 1 Nausea 31 1 Constipation 16 <1 Dyspepsia 11 <1 Hepatobiliary Uncommon Hepatic failure*,# <1 <1 disorders Skin and Very Rash* 34 3 subcutaneous common tissue disorders Common Urticaria 1 <1 Erythema 3 <1 Onychoclasis 4 0 Uncommon Angioedema <1 <1 Panniculitis* <1 <1 Neutrophilic dermatoses* <1 <1 Pyogenic granuloma <1 0 Cutaneous vasculitis <1 0 Rare Stevens-Johnson syndrome <1 <1 Musculoskeletal Very Arthralgia 24 2 and connective common Muscle spasms 15 <1 tissue disorders Musculoskeletal pain* 36 3 Renal and urinary Common Acute kidney injury# <2 <1 disorders General disorders Very Pyrexia 19 1 and administration common Oedema peripheral 16 1 site conditions Investigations Very Blood creatinine increased 10 <1 common † Frequencies are rounded to the nearest integer. * Includes multiple adverse reaction terms. ‡ In some cases associated with loss of vision. # Includes events with fatal outcome. @ Lower level term (LLT) used for selection.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T15:30:00Z · SHA-256 a9cee31168a81381e2e0315390c7e6008548b2272679979bce5eb1784595366b · Passage afccb8f7c72e5f0c6fa5369f917d3eaf7fa750e00854de3a498c9ddd9010f1d1 · Zeichen 5854–8709 im Abschnitt